Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation (CDER), urged members of Congress to pass the reauthorizations of the Biosimilar User Fee Act (BsUFA) and the Generic Drug User Fee Act (GDUFA). Woodcock testified before the House Energy and Commerce Committee on March 2, 2017.
Congress has already agreed upon details of the reauthorizations, but they need to be finalized before the end of September 2017 for the FDA to continue receiving funding to ensure timely review of biosimilars and generics over the next 5 years. “Many of our most important drugs are biological products,” Woodstock said. “It is important for the public health of the US population to have access to safe, effective, and affordable biological products. Biosimilars can provide more treatment options for patients, and possibly lower treatment costs, enabling greater access for more patients.” According to Woodcock, 64 biosimilars in development are expected to provide competition for 23 biologics.
Rigorous review and approval standards are essential to earn physicians’ and patients’ confidence in biosimilar and interchangeable products, Woodcock explained, and they are key to the success of the biosimilar program. The FDA cannot achieve these goals without adequate funding in place.
While FDA has made significant progress in creating and implementing the biosimilar program, there is more work to do and challenges that must be addressed, Woodcock said. The ability to hire the right staff is key to ensuring timely review of new biosimilars, and the agency is committed to recruit and retain the critical scientific, technical, and professional talent needed to address complex and often novel scientific and legal issues involved in biosimilar review, she added. But the lack of additional staffing to handle the increased workload for biosimilar review has affected review performance, she told members of Congress. For example, in 2015, the FDA was able to schedule only 50% of initial advisory meetings within the 90-day meeting goal. While 2016 saw an improvement, the agency continued to face challenges and was unable to meet some performance goals.
In the FDA’s discussions with industry, biosimilar producers said they would like to see more meetings and faster turnaround of Agency advice in the reauthorized BsUFA. “BsUFA I provided critically needed funding for FDA to implement the beginning of a successful biosimilars program,” said Woodcock. “BsUFA II will allow the FDA to continue building this program and make improvements where needed.” She said the new pathway for biosimilar and interchangeable products has the potential to offer a significant contribution to the public health of many Americans by increasing access to more affordable biologics. “At FDA, we are working hard to ensure this positive impact can be realized,” she concluded. “We are optimistic and energized about the future of biosimilars.”
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
2 Commerce Drive
Cranbury, NJ 08512